Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Hepatocellular Carcinoma | Research

Elevated FAM134B expression induces radiation-sensitive in hepatocellular carcinoma

Authors: Binhui Xie, Yuankang Xie, Cuifu Fang, Baiyin Zhong, Rong Ye, Jianhong Zhang, Qingquan Liu, Heping Li

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Previous studies have shown that Family with sequence similarity 134 member B (FAM134B) was involved in the occurrence and development of malignancy, however, the function and molecular mechanism of FAM134B in Hepatocellular Carcinoma (HCC) radiotherapy resistance remain unclear. Therefore, it may clinical effective to clarify the molecular mechanism and identify novel biomarker to overcome radiotherapy resistance in HCC.

Methods

The protein and mRNA expression of FAM134B were determined using Real-time PCR and Western blot, respectively. IHC assay was performed to investigate the association between FAM134B expression and the clinicopathological characteristics of 132 HCC patients. Functional assays, such as in situ model, colon formation, FACS, and Tunel assay were used to determine the oncogenic role of FAM134B in human HCC progression. Furthermore, western blotting and luciferase assay were used to determine the mechanism of FAM134B promotes radiation-sensitive in HCC cells.

Results

We noted that FAM134B was downregulated in HCC, which was correlated with the radiation resistance in patients with HCC. Overexpression of FAM134B contribute to radiation sensitive in HCC; however, inhibition of FAM134B confers HCC cell lines to radiation resistance both in vitro and in vivo. Moreover, we found that FAM134B interacts with FMS related receptor tyrosine kinase 3 (FLT3) and downregulation of FAM134B activated JAK/Stat3 signaling pathway. Importantly, pharmacological inhibition of JAK/Stat3 signaling pathway significantly counteracted downregulation of FAM134B-induced radiation resistance and enhanced radiation therapeutic efficacy in HCC.

Conclusions

Our findings suggest that FAM134B may be a potential therapeutic biomarker for the treatment of HCC patients with radiotherapy tolerance.
Appendix
Available only for authorised users
Literature
1.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–386.CrossRefPubMed
2.
Marengo A, Rosso C, Bugianesi E. Liver Cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med. 2016;67:103–17.CrossRefPubMed
3.
Clark T, Maximin S, Meier J, Pokharel S, Bhargava P. Hepatocellular Carcinoma: review of Epidemiology, Screening, Imaging diagnosis, Response Assessment, and treatment. Curr Probl Diagn Radiol. 2015;44(6):479–86.CrossRefPubMed
4.
Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis. J Carcinog 2017, 16:1.
5.
Wahl DR, Stenmark MH, Tao Y, Pollom EL, Caoili EM, Lawrence TS, Schipper MJ, Feng M. Outcomes after stereotactic body radiotherapy or Radiofrequency ablation for Hepatocellular Carcinoma. J Clin oncology: official J Am Soc Clin Oncol. 2016;34(5):452–9.CrossRef
6.
Wang J, Li Q, Sun Y, Zheng H, Cui Y, Li H, Zhou H, Hao X. Clinicopathologic features between multicentric occurence and intrahepatic metastasis of multiple hepatocellular carcinomas related to HBV. Surg Oncol. 2009;18(1):25–30.CrossRefPubMed
7.
Couri T, Pillai A. Goals and targets for personalized therapy for HCC. Hep Intl. 2019;13(2):125–37.CrossRef
8.
Kishore SA, Bajwa R, Madoff DC. Embolotherapeutic strategies for Hepatocellular Carcinoma: 2020 update. Cancers 2020, 12(4).
9.
Lee SY, Jeong EK, Ju MK, Jeon HM, Kim MY, Kim CH, Park HG, Han SI, Kang HS. Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation. Mol Cancer. 2017;16(1):10.CrossRefPubMedPubMedCentral
10.
Fu SM, Xu MX, Lin SM, Liang Z, Cai JH. Association of cyclin D1 and survivin expression with sensitivity to radiotherapy in patients with nasopharyngeal carcinoma. Genet Mol research: GMR. 2014;13(2):3502–9.CrossRefPubMed
11.
12.
Sehedic D, Cikankowitz A, Hindre F, Davodeau F, Garcion E. Nanomedicine to overcome radioresistance in glioblastoma stem-like cells and surviving clones. Trends Pharmacol Sci. 2015;36(4):236–52.CrossRefPubMed
13.
Sun Q, Liu T, Zhang T, Du S, Xie GX, Lin X, Chen L, Yuan Y. MiR-101 sensitizes human nasopharyngeal carcinoma cells to radiation by targeting stathmin 1. Mol Med Rep. 2015;11(5):3330–6.CrossRefPubMedPubMedCentral
14.
Islam F, Gopalan V, Lam AK. RETREG1 (FAM134B): a new player in human diseases: 15 years after the discovery in cancer. J Cell Physiol. 2018;233(6):4479–89.CrossRefPubMed
15.
Islam F, Gopalan V, Law S, Tang JC, Lam AK. FAM134B promotes esophageal squamous cell carcinoma in vitro and its correlations with clinicopathologic features. Hum Pathol. 2019;87:1–10.CrossRefPubMed
16.
Haque MH, Gopalan V, Chan KW, Shiddiky MJ, Smith RA, Lam AK. Identification of Novel FAM134B (JK1) mutations in Oesophageal squamous cell carcinoma. Sci Rep. 2016;6:29173.CrossRefPubMedPubMedCentral
17.
18.
Oakes SA, Papa FR. The role of endoplasmic reticulum stress in human pathology. Annu Rev Pathol. 2015;10:173–94.CrossRefPubMed
19.
Yamasaki S, Yagishita N, Nishioka K, Nakajima T. The roles of synoviolin in crosstalk between endoplasmic reticulum stress-induced apoptosis and p53 pathway. Cell Cycle. 2007;6(11):1319–23.CrossRefPubMed
20.
Zhang ZQ, Chen J, Huang WQ, Ning D, Liu QM, Wang C, Zhang L, Ren L, Chu L, Liang HF, et al. FAM134B induces tumorigenesis and epithelial-to-mesenchymal transition via akt signaling in hepatocellular carcinoma. Mol Oncol. 2019;13(4):792–810.CrossRefPubMedPubMedCentral
21.
Forman OP, Hitti RJ, Pettitt L, Jenkins CA, O’Brien DP, Shelton GD, De Risio L, Quintana RG, Beltran E, Mellersh C. An inversion disrupting FAM134B is Associated with sensory neuropathy in the Border Collie Dog Breed. G3. 2016;6(9):2687–92.CrossRefPubMedPubMedCentral
22.
Kuvshinoff BW, Ota DM. Radiofrequency ablation of liver tumors: influence of technique and tumor size. Surgery. 2002;132(4):605–11. discussion 611 – 602.CrossRefPubMed
23.
Li Q, Wang J, Juzi JT, Sun Y, Zheng H, Cui Y, Li H, Hao X. Clonality analysis for multicentric origin and intrahepatic metastasis in recurrent and primary hepatocellular carcinoma. J Gastrointest surgery: official J Soc Surg Aliment Tract. 2008;12(9):1540–7.CrossRef
24.
Davila JA, Duan Z, McGlynn KA, El-Serag HB. Utilization and outcomes of palliative therapy for hepatocellular carcinoma: a population-based study in the United States. J Clin Gastroenterol. 2012;46(1):71–7.CrossRefPubMed
25.
Schwarz RE, Smith DD. Trends in local therapy for hepatocellular carcinoma and survival outcomes in the US population. Am J Surg. 2008;195(6):829–36.CrossRefPubMed
26.
Boriachek K, Islam MN, Gopalan V, Lam AK, Nguyen NT, Shiddiky MJA. Quantum dot-based sensitive detection of disease specific exosome in serum. Analyst. 2017;142(12):2211–9.CrossRefPubMed
27.
Kasem K, Sullivan E, Gopalan V, Salajegheh A, Smith RA, Lam AK. JK1 (FAM134B) represses cell migration in colon cancer: a functional study of a novel gene. Exp Mol Pathol. 2014;97(1):99–104.CrossRefPubMed
28.
Islam F, Gopalan V, Wahab R, Smith RA, Qiao B, Lam AK. Stage dependent expression and tumor suppressive function of FAM134B (JK1) in colon cancer. Mol Carcinog. 2017;56(1):238–49.CrossRefPubMed
29.
Islam F, Gopalan V, Pillai S, Lu CT, Kasem K, Lam AK. Promoter hypermethylation inactivate tumor suppressor FAM134B and is associated with poor prognosis in colorectal cancer. Genes Chromosomes Cancer. 2018;57(5):240–51.CrossRefPubMed
30.
Corcoran RB, Contino G, Deshpande V, Tzatsos A, Conrad C, Benes CH, Levy DE, Settleman J, Engelman JA, Bardeesy N. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res. 2011;71(14):5020–9.CrossRefPubMedPubMedCentral
31.
Hussain SF, Kong LY, Jordan J, Conrad C, Madden T, Fokt I, Priebe W, Heimberger AB. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res. 2007;67(20):9630–6.CrossRefPubMed
32.
Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, Fokt I, Hess K, Conrad C, Madden T, Sawaya R, et al. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene. 2007;26(17):2435–44.CrossRefPubMed
33.
Chen X, Ying Z, Lin X, Lin H, Wu J, Li M, Song L. Acylglycerol kinase augments JAK2/STAT3 signaling in esophageal squamous cells. J Clin Investig. 2013;123(6):2576–89.CrossRefPubMedPubMedCentral
Metadata
Title
Elevated FAM134B expression induces radiation-sensitive in hepatocellular carcinoma
Authors
Binhui Xie
Yuankang Xie
Cuifu Fang
Baiyin Zhong
Rong Ye
Jianhong Zhang
Qingquan Liu
Heping Li
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11030-x

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

The prognostic significance of tumor-associated neutrophils and circulating neutrophils in glioblastoma (WHO CNS5 classification)

Research

Prognostic value of Hematoxylin and eosin staining tumor-infiltrating lymphocytes (H&E-TILs) in patients with esophageal squamous cell carcinoma treated with chemoradiotherapy

Research article

Altered expression of the L-arginine/nitric oxide pathway in ovarian cancer: metabolic biomarkers and biological implications

Research

Plasma ctDNA increases tissue NGS-based detection of therapeutically targetable mutations in lung cancers

Study protocol

Association of Radiochemotherapy to Immunotherapy in unresectable locally advanced Oesophageal carciNoma—randomized phase 2 trial ARION UCGI 33/PRODIGE 67: the study protocol

Research

The impact of COVID-19 on national program of colorectal cancer screening in Tehran, Iran: a multicenter study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits